The patient was treated with rituximab, cyclophosphamide, epirubicin,
vindesine, and prednisone for 6 courses and remained in partial remission till now.
The patient underwent 4 cycles of chemotherapy with ABVD (doxorubicin, bleomycin,
vindesine, and dacarbazine).
Neurotoxic Agents by Class Class Medications Bortezomib Cytomib[R], Velcade[R] Platinum compounds Cisplatin (Platinol[R]) Carboplatin (Paraplatin[R]) Oxaliplatin (Eloxatin[R]) Taxanes Paclitaxel (Abraxane[R], Taxol[R]) Docetaxel (Taxotere[R]) Thalidomide, lenalidomide Thalomid[R], REVLIMID[R] Vinca alkaloids Vincristine (Oncovin[R]) Vnblastine
Vindesine Vinorelbine (Navelbine[R]) Source: Naleschinski et al., 2012 TABLE 3.
Well known examples include Vinca alkaloids (vincristine, vinblastine,
vindesine, vinorelbine), taxanes (paclitaxel, docetaxel), epipodophyllotoxines (etoposide, teniposide), camptothecine and its derivatives (topothecan, irinothecan), and anthracydines (doxorubicin, daunorubicin, epirubicine, idarubicin).
A recent update of randomised trials conducted by the GELA group and others evaluating the efficacy of rituximab in addition to CHOP or intensified CHOP (namely, ACVBP: 75mg/[m.sup.2] doxorubicin and 1200 mg/[m.sup.2] cyclophosphamide on day 1; 2mg/[m.sup.2]
vindesine and 10 mg bleomycin on days 1 and 5; and 60 mg/[m.sup.2] prednisone on days 1-5) demonstrated that the benefit of rituximab is maintained over the years [1-7].
Postoperatively, the patient underwent five courses of chemotherapy with the R-THP-CVP regimen (rituximab, pirarubicin, doxorubicin, hydrochloride, cyclophosphamide hydrate,
vindesine sulfate, and prednisolone).
Combination chemotherapy with doxorubicin, bleomycin and
vindesine for AIDS-related Kaposi's sarcoma.